Meniscus is more susceptible than cartilage to catabolic and anti-anabolic effects of adipokines  by Nishimuta, J.F. & Levenston, M.E.
Osteoarthritis and Cartilage 23 (2015) 1551e1562Meniscus is more susceptible than cartilage to catabolic and
anti-anabolic effects of adipokines
J.F. Nishimuta y, M.E. Levenston y z *
y Department of Mechanical Engineering, Stanford University, Stanford, CA 94305, USA
z Department of Bioengineering, Stanford University, Stanford, CA 94305, USAa r t i c l e i n f o
Article history:
Received 12 June 2014
Accepted 15 April 2015
Keywords:
Meniscus
Cartilage
Adipokines
Degeneration
Obesity
Osteoarthritis* Address correspondence and reprint requests to:
of Mechanical Engineering, Stanford University, Sta
Tel: 1-650-723-9464; Fax: 1-650-725-1587.
E-mail addresses: j.nishimuta@gmail.com (J.F. Nishim
(M.E. Levenston).
http://dx.doi.org/10.1016/j.joca.2015.04.014
1063-4584/© 2015 Osteoarthritis Research Society Ins u m m a r y
Objective: This study compared the effects on cartilage and meniscus matrix catabolism and biosynthesis
of several adipokines implicated in osteoarthritis (OA).
Design: Bovine cartilage and meniscus explants were cultured for 1 or 9 days in serum-free medium
alone or with 0.02, 0.2, or 2 mg/ml of leptin, visfatin, adiponectin, or resistin. Media were supplemented
with 3H-proline or 35S-sodium sulfate to evaluate protein and sulfated glycosaminoglycan (sGAG)
accumulation on the last day of culture. Explants were assayed for radiolabel, sGAG, and DNA contents.
Cultured media were assayed for sGAG, nitrite and lactate dehydrogenase.
Results: Cartilage tissue was minimally affected by adipokines, with only the highest resistin dose
increasing sGAG release and nitrite production compared to controls. In sharp contrast, meniscus tissue
was responsive to several adipokines, with elevated sGAG and nitrite release following treatment with
resistin, leptin, or visfatin. Cartilage sGAG content was unaltered by adipokine treatment whereas
meniscal sGAG content signiﬁcantly decreased with resistin dosage. Protein (3H) incorporation was
unaffected by adipokine treatment in both tissues. sGAG (35S) incorporation did not signiﬁcantly vary
with adipokine treatment in cartilage but was inhibited by treatment with leptin, visfatin, and resistin in
meniscus.
Conclusion: Our results indicate that meniscal tissue is more susceptible to adipokine-stimulated
catabolism than is cartilage. Resistin had the strongest effect of the adipokines tested, inducing sGAG
release in both tissues and depleting sGAG content in meniscus. These results suggest that increased
adipokine levels due to obesity or joint injury may alter the mechanical integrity of the knee joint
through biological pathways.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Obesity in developed nations is at epidemic levels, with preva-
lence among US adults estimated at 36% in 2009e101 and predicted
to reach about 50% by 20302. Obesity is a major risk factor for hip
and knee osteoarthritis (OA), with every 5 unit increase in body
mass index (BMI) doubling the risk of OA3. The association between
obesity and OA has been viewed as predominantly biomechanical4,
but overloading may not be the only link. Knee OA incidence and
progressionwere more strongly associated with fat mass thanwithM.E. Levenston, Department
nford, CA 94305-4038, USA.
uta), levenston@stanford.edu
ternational. Published by Elsevier LBMI or total mass5, and obesity has been identiﬁed as a strong risk
factor for hand OA6,7, suggesting that systemic, biologic links be-
tween obesity and OA may exist in addition to direct mechanical
effects.
Adipose tissue is now recognized as a metabolically active or-
gan8 that secretes biologically active factors collectively described
as adipokines. Altered adipokine levels have been implicated in
diabetes, cardiovascular disease, metabolic syndrome, and inﬂam-
matory disorders including rheumatoid arthritis9. With observa-
tions of adipokines including leptin10, visfatin11, adiponectin and
resistin12 in the synovial ﬂuid of osteoarthritic joints, roles for
adipokines in the onset and progression of OA have been hypoth-
esized13. In the knee, the synovium and infrapatellar fat pad have
been identiﬁed as major adipokine producers14,15. Elevated lep-
tin10,16, resistin17,18, and visfatin19,20 levels in both serum and sy-
novial ﬂuid have been associated with increased OA progression ortd. All rights reserved.
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unclear21,22.
In OA joints, synovial ﬂuid concentrations range around
10e20 ng/mL for leptin10,14,16, 10e40 ng/mL for visfatin19,20,
0.3e2.3 mg/ml for adiponectin12,14,23, and 3e50 ng/mL for resis-
tin12,14,17. Increased BMI correlates with elevated synovial ﬂuid
concentrations of leptin10 but lower synovial ﬂuid concentrations
of adiponectin21,24. While studies have reported no correlation
between synovial ﬂuid concentrations of visfatin20 or resistin24 and
BMI, both correlated with OA severity.
Various adipokines have induced cell-mediated cartilage
catabolism in vitro. Leptin induced production of proinﬂammatory
factors and enhanced matrix metalloproteinase (MMP) expression
in OA cartilage25,26. Visfatin stimulated chondrocyte aggrecanase
expression and MMP production11, while adiponectin induced
production and expression of several MMPs and proinﬂammatory
factors22,27. Resistin induced production of proinﬂammatory factors
and inhibited matrix synthesis in mouse cartilage17 and increased
aggrecanase and MMP expression by human chondrocytes28.
Particularly relevant to the potential involvement of adipokines in
OA development, serum and synovial ﬂuid level of resistin were
elevated following traumatic joint injury (median resistin level
approximately 3 ng/ml 1 week following injury)17.
However, little is known about the effects of adipokines on joint
tissues other than articular cartilage. A recent investigation
demonstrated that 100 ng/ml visfatin increased nitric oxide pro-
duction and MMP activity or matrix degradation in adult porcine
cartilage and meniscus29. Particularly given growing evidence that
meniscal degeneration is an early event in knee OA that accom-
panies or precedes cartilage degeneration30,31, a more detailed
understanding of the effects of catabolic mediators on meniscal
metabolism is desirable. The goals of this study were to evaluate
dose-dependent catabolic and anti-anabolic effects of leptin, vis-
fatin, adiponectin and resistin on cartilage and meniscus tissue
explants, and to examine the relative susceptibility of these tissues
to each adipokine.
Method
Materials
Immature bovine stiﬂes were from Research 87 (Marlborough,
MA). High glucose Dulbecco'smodiﬁed Eagle'smedium (DMEM)was
from HyClone (Logan, UT). Non-essential amino acids (NEAA) and
proteinase K were from Life Technologies (Carlsbad, CA). N-(2-
hydroxyethyl)-piperazine-N0-2-ethanesulfonic acid (HEPES), genta-
micin and phosphate buffered saline (PBS) were from Mediatech
(Manassas, VA). Insulin-transferrin-selenous acid premix (ITSþ) was
fromBDBiosciences (Franklin Lakes, NJ). L-ascorbic acid 2-phosphate,
proline, ammonium acetate, 1,9-dimethyl-methylene blue (DMMB),
shark chondroitin sulfate, sodium nitrite, bisbenzimide (Hoechst
33258), and calf thymus DNA were from Sigma (St. Louis, MO). Sul-
fanilamide reagent and naphthylethylenediamine dihydrochloride
solution were from Ricca Chemical (Arlington, TX). The CytoTox-
ONE™ Homogeneous Membrane Integrity assay kit was from
Promega (Madison, WI). 3H-proline and 35S-sodium sulfate were
from PerkinElmer (Waltham, MA). Recombinant human leptin was
fromShenandoahBiotechnology (Warwick, PA), recombinant human
visfatin was from Novus Biologicals (Littleton, CO), and recombinant
human adiponectin and resistin were from BioVendor (Candler, NC).
Experimental design
Independent experiments evaluated the effects of initial (1 day)
and sustained (9 day) exposure to adipokines. Both experimentsinvolved two substudies, each consisting of an untreated control
group and three doses (0.02, 0.2 and 2 mg/ml) of two adipokines:
leptin and visfatin in one substudy, adiponectin and resistin in the
other. Tissue explants for each substudy were isolated from four
immature bovine stiﬂes (one each from four animals, total of
sixteen donors), and samples from different donors and relative
positions (anterior, central, posterior) were distributed across
experimental groups (n ¼ 6e8 explants/tissue/condition).
Tissue culture
Using a 4 mm biopsy punch, full thickness explants were iso-
lated from the lateral femoral condylar cartilage and the caudal
surface of the radially middle region of lateral menisci from bovine
stiﬂes. Explants were cultured at 37C, 5% CO2, and 95% relative
humidity in basal, serum-free medium consisting of high glucose
DMEM with 0.1 mM NEAA, 10 mM HEPES buffer, 50 mg/ml L-
ascorbic acid-2-PO4, 50 mg/ml gentamicin, 0.4 mM proline, and 1%
ITSþ premix. After overnight culture, explants were trimmed to
2 mm thickness retaining intact articular surfaces.
Radiolabeled cultured media were prepared with 20 mCi/ml of
3H-proline and 10 mCi/ml of 35S-sodium sulfate to label biosynthesis
of proteins and sulfated glycosaminoglycans (sGAGs), respectively.
In the ﬁrst experiment, explants were cultured for 22 h in radio-
labeled basal medium alone (control) or supplemented with 0.02,
0.2, or 2 mg/ml of adipokines, as described above. In the second
experiment, explants were cultured for 8 days in radiolabel-free
media supplemented with adipokines, with media exchanges
every 48 h. Explants were then cultured for an additional 22 h in
media supplemented with radiolabels to assess chronic effects of
adipokines on biosynthesis. Conditioned media were collected and
stored at 20C for later analysis.
Biochemistry
Explants were washed four times for 30 min each at 4C in PBS
supplemented with 0.8 mM sodium sulfate and 1.0 mM L-proline to
remove unincorporated radiolabels. Explants were weighed,
lyophilized overnight and re-weighed dry, then digested overnight
at 60C in 1 ml proteinase K (1 mg/40 mg cartilage wet mass, 1 mg/
20 mg meniscus wet mass) buffered with 100 mM ammonium
acetate. Digest radiolabel contents were measured using a liquid
scintillation counter. Explant DNA contents were measured using
the Hoechst 33258 assay32 with calf thymus DNA standards.
Sulfated glycosaminoglycan (sGAG) contents of digested explants
and conditioned media were assayed using the dimethylmethylene
blue (DMMB) assay33 with chondroitin sulfate standards ranging
from 0 to 100 mg/ml. To estimate production of nitric oxide (NO), a
cell signaling mediator in inﬂammation34, nitrite contents of
conditioned media were measured using the Griess assay35 with
sodium nitrite standards ranging from 0 to 100 mM. Lactate dehy-
drogenase (LDH), a surrogate indicator of cell lysis, wasmeasured in
conditioned media from the 9-day culture studies using the Cyto-
Tox-ONE™ kit with puriﬁed LDH from ﬁbrocytes as standards. As
necessary, samples were diluted to remain in the linear region of
each assay.
Data analysis
Radiolabel incorporation of each explant was normalized to its
DNA content. All data were log transformed to improve normality.
Statistical analyses were performed using Minitab 17 (Minitab, Inc.,
State College, PA). For each experiment, responses for each adipo-
kine were analyzed using general linear models (GLMs) and Bon-
ferroni's test for planned pairwise comparisons. Tissue and
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animal as a random factor and position (anterior, central, posterior)
nested within tissue to account for baseline regional differences.
The Anderson-Darling test was performed to verify normality of
residuals; in rare instances individual outcomes had non-normal
residuals due to outliers, but elimination of outliers did not alter
main ﬁndings. Signiﬁcance was set at P < 0.05 and values are
presented as means with 95% conﬁdence intervals (lower limit,
upper limit).
Results
sGAG release
Initial effects
In the adiponectin-resistin substudy, cartilage controls and
adiponectin at all doses exhibited higher sGAG release than cor-
responding meniscus groups (Fig. 1; all P < 0.001). For cartilage,
none of the adipokines signiﬁcantly elevated sGAG release on day 1
compared to tissue-matched controls. In contrast, meniscus sGAG
release on day 1 was signiﬁcantly greater than tissue-matched
controls for leptin at 2 mg/ml, visfatin at 2 mg/ml and resistin at
all doses (all P < 0.001). Leptin, visfatin, adiponectin and resistin
induced release of 24.1% (2.6%, 45.5%), 22.8% (5.0%, 40.5%), 1.4%
(1.2%, 1.6%) and 32.0% (17.8%, 46.3%) of total sGAG, respectively, as
compared to 2.3% (1.6%, 2.9%) and 1.4% (0.8%, 1.9%) for controls in
the two substudies. Additionally, meniscus treated with leptin
(2 mg/ml, P ¼ 0.032) visfatin (2 mg/ml, P < 0.001) or resistin (0.2 mg/
ml, P ¼ 0.001; 2 mg/ml, P < 0.001) exhibited higher sGAG release
than cartilage with corresponding treatments, despite the sub-
stantially lower sGAG contents of meniscus explants.
Sustained treatment effects
sGAG release from controls was greater for cartilage than for
meniscus throughout the 9-day culture duration in both substudies
(Fig. 2). As a fraction of total measured sGAG, however, 8-day sGAGFig. 1. Initial effects of adipokines on sGAG release. sGAG contents of conditioned media fr
the difference in scaling between cartilage and meniscus. *P < 0.05 relative to tissue-matche
treatment, yP < 0.05 relative to cartilage at the same treatment and dose.release from controls was signiﬁcantly greater for meniscus than
for cartilage (24.6% (19.8%, 29.5%) vs 5.8% (5.3%, 6.2%)), consistent
with previous observations36. Cartilage sGAG release was not
signiﬁcantly affected by any adipokine treatment throughout the
culture duration. In contrast, meniscus sGAG release on day 2 was
elevated by treatment with 2 mg/ml leptin, 2 mg/ml visfatin and all
concentrations of resistin (all P < 0.001 vs controls). Elevated sGAG
release continued through 4 days for meniscus treatedwith 2 mg/ml
(P < 0.001) or 0.2 mg/ml (P ¼ 0.023) leptin, 2 mg/ml visfatin
(P¼ 0.011), and all concentrations of resistin (all P < 0.001). Later in
the culture period, meniscus samples treated with resistin exhibi-
ted lower sGAG release than controls on day 6 at 2 mg/ml
(P ¼ 0.003) and on day 8 at 0.2 mg/ml (P ¼ 0.003) and 2 mg/ml
(P  0.001), likely reﬂecting substantial sGAG depletion. Over 8
days, leptin, visfatin, adiponectin and resistin induced cumulative
release of 29.6% (32.9%, 35.4%), 38.4% (23.1%, 53.8%), 35.8% (24.9%,
46.8%) and 62.7% (51.6%%, 73.8%) of measured sGAG, respectively, as
compared to 20.0% (14.2%, 25.8%) and 29.3% (22.3%, 36.3%) for
controls in the two substudies. Consistent with the results for im-
mediate release, treatment with 0.2e2 mg/ml resistin elevated
meniscus sGAG release relative to cartilage with the same treat-
ment on day 2 of culture (both P < 0.001), particularly notable given
the substantial disparity in sGAG content between cartilage and
meniscus tissues.
Nitrite release
Initial effects
Nitrite release patterns on day 1 (Fig. 3) generally paralleled
sGAG release. In the adiponectin-resistin substudy, day 1 nitrite
release was greater in cartilage for controls (P ¼ 0.035) and adi-
ponectin groups (all P < 0.001). In cartilage, nitrite release was not
signiﬁcantly elevated above controls for any adipokine. In contrast,
leptin (2 mg/ml, P < 0.001), visfatin (2 mg/ml, P < 0.001) and all doses
of resistin (0.02 mg/ml, P ¼ 0.004; 0.2 and 2 mg/ml, P < 0.001)
signiﬁcantly elevated day 1 nitrite release in meniscus aboveom cartilage (AeB) and meniscus (CeD) explants treated with adipokines for 22 h. Note
d controls, #P < 0.05 relative to 0.02 mg/ml treatment, %P < 0.05 relative to 0.20 mg/ml
Fig. 2. Effects of sustained adipokine exposure on sGAG release. 48-hour sGAG release to media from cartilage (left column) and meniscus (right column) explants treated with
adipokines for 8 days. *P < 0.05 relative to tissue-matched controls, #P < 0.05 relative to 0.02 mg/ml treatment, yP < 0.05 relative to cartilage at the same treatment and dose,
P^ < 0.05 relative to cartilage for some groups.
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cartilage samples treated with visfatin (2 mg/ml, P < 0.001) or
resistin (0.2 mg/ml, P ¼ 0.042; 2 mg/ml, P ¼ 0.002), with a trend
towards greater release with leptin (2 mg/ml, P ¼ 0.059).
Sustained treatment effects
Dose-dependent nitrite release patterns (Fig. 4) were similar to
sGAG release patterns. On day 2 of both substudies, cartilage con-
trols had greater nitrite release than meniscus controls (both
P < 0.001). Cartilage nitrite release was signiﬁcantly increasedrelative to controls only by 2 mg/ml resistin on day 2 (P¼ 0.001) and
day 4 (P¼ 0.004). Meniscus nitrite release on day 2 was elevated by
treatment with all leptin doses (all P < 0.001), 2 mg/ml visfatin
(P < 0.001) and all resistin doses (0.02 mg/ml, P ¼ 0.001; 0.2 and
2 mg/ml, P < 0.001). Elevated nitrite release continued through day
4 of the culture duration for meniscus treated with 2 mg/ml resistin
(P ¼ 0.004). Additionally, 2 mg/ml visfatin (P < 0.001) and 0.2 and
2 mg/ml resistin (both P < 0.001) elevated meniscus nitrite release
on day 2 relative to cartilage with the same treatment, despite the
lower baseline (control) nitrite production for meniscus.
Fig. 3. Initial effects of adipokines on nitrite release. Nitrite content of conditioned media from cartilage (AeB) and meniscus (CeD) explants treated with adipokines for 22 h.
Note the difference in scaling between cartilage and meniscus. *P < 0.05 relative to tissue-matched controls, #P < 0.05 relative to 0.02 mg/ml treatment, %P < 0.05 relative to 0.20 mg/
ml treatment, yP < 0.05 relative to cartilage at the same treatment and dose.
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LDH release, a surrogate measure of cell lysis, was not signiﬁ-
cantly above controls for any adipokine for either tissue, suggesting
that the doses examined were not cytotoxic. All leptin doses
decreased LDH release relative to controls on days 2, 4 and 8 (all
P < 0.01).
Explant composition
Initial effects
In both substudies, cartilage explants had greater water
(P < 0.001) and DNA (P < 0.001) contents than meniscus explants,
and water content was unaffected by any adipokine treatment.
Cartilage DNA content was lower than controls for adiponectin at
0.02 mg/ml (P < 0.001) but not for any other treatment, and
meniscus DNA content did not vary with adipokine treatment.
sGAG content (Fig. 5) was greater in cartilage than in meniscus
(P < 0.001) in both substudies, indicative of differences in native
tissue composition. Cartilage sGAG content did not vary with 1 day
of adipokine treatment. Meniscus sGAG content after 1 day of
culture was lower with 2 mg/ml resistin than with 0.02 mg/ml
resistin (P ¼ 0.002), but otherwise showed no signiﬁcant
variations.
Sustained treatment effects
Cartilage explants after the 9-day culture had greater water
(P < 0.001), DNA (P < 0.001) and sGAG (Fig. 6, P < 0.001) contents
than meniscus explants. Adipokine treatments did not signiﬁcantly
alter water or DNA contents for either tissue or sGAG content for
cartilage. Meniscus sGAG content was signiﬁcantly decreased
relative to tissue-matched controls by resistin at 0.2 (P ¼ 0.001) or
2 mg/ml (P < 0.001), and was signiﬁcantly lower at 2 mg/ml than at
0.02 mg/ml (P < 0.001), but was not signiﬁcantly altered by other
adipokines.Biosynthesis
Initial effects
3H-proline incorporation on day 1 of culture [Fig. 7(AeD)] was
signiﬁcantly greater for cartilage than for meniscus in the leptin-
visfatin substudy (P < 0.001) but not in the adiponectin-resistin
substudy. 35S-sulfate incorporation on day 1 [Fig. 7(EeH)] was
signiﬁcantly (and substantially) greater in cartilage than in
meniscus explants in both substudies (P < 0.001), consistent with
the higher baseline sGAG synthesis rate of cartilage.
Treatment with adipokines did not signiﬁcantly alter 3H-pro-
line incorporation on day 1 compared to tissue-matched controls.
3H-proline incorporation was lower with visfatin at 2 mg/ml than
at 0.02 mg/ml (P ¼ 0.037) with no interaction with tissue, but
there were no other signiﬁcant effects of adipokine dose. In
contrast, 35S-sulfate incorporation on day 1 exhibited dose-
dependent responses to several adipokines. 35S-sulfate incorpo-
ration was lower for visfatin at 2 mg/ml than at 0.02 mg/ml
(P ¼ 0.017) or controls (P ¼ 0.045), with no interaction with
tissue. Leptin signiﬁcantly affected meniscus 35S-sulfate incor-
poration, with lower values at 2 mg/ml than at 0.2 mg/ml
(P ¼ 0.004), 0.02 mg/ml (P < 0.001) or in controls (P ¼ 0.045).
Similarly, resistin signiﬁcantly affected meniscus 35S-sulfate
incorporation, with lower values at 2 mg/ml than at 0.02 mg/ml
(P ¼ 0.009) or in controls (P ¼ 0.028), and lower values at 0.2 mg/
ml than at 0.02 mg/ml (P ¼ 0.043).
Sustained treatment effects
Effects of adipokines on radiolabel incorporation rates were
fairly minor by day 9 of culture. Both 3H-proline incorporation and
35S-sulfate incorporation (Fig. 8) were signiﬁcantly greater in
cartilage explants than in meniscus explants in both substudies (all
P< 0.001). 3H-proline incorporationwas not signiﬁcantly altered by
any adipokine treatment in either tissue. For meniscus, 35S-sulfate
incorporation was signiﬁcantly lower with 2 mg/ml visfatin than
Fig. 4. Effects of sustained adipokine exposure on nitrite release. 48-hour nitrite levels in conditioned media from cartilage (left column) and meniscus (right column) explants
treated with adipokines for 8 days. Note the differences in scaling. *P < 0.05 relative to tissue-matched controls, #P < 0.05 relative to 0.02 mg/ml treatment, %P < 0.05 relative to
0.20 mg/ml treatment, yP < 0.05 relative to cartilage at the same treatment and dose, P^ < 0.05 relative to cartilage for some groups.
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signiﬁcant effects of adipokines.
Discussion
While systemic and local effects of obesity-related biochemical
signals have received increasing attention as non-mechanical links
between excess fat and joint degeneration, few studies have
compared the effects of these factors on different tissues involvedin early stage OA. The current studies evaluated catabolic and anti-
anabolic effects on cartilage and meniscus explants of several adi-
pokines present in synovial ﬂuid and implicated in the develop-
ment of OA. In meniscus explants, leptin, visfatin and resistin all
stimulated sGAG release and nitrite production while inhibiting to
varying degrees incorporation of newly synthesized sGAG. Effects
on cartilage were relatively minor, with the only signiﬁcant effects
being initial reduction of matrix synthesis at the highest visfatin
dose and elevated nitrite production with the highest resistin dose.
Fig. 5. Initial effects of adipokines on explant sGAG content. sGAG content of cartilage (AeB) and meniscus (CeD) explants treated with adipokines for 22 h. Note difference in
vertical axes between cartilage and meniscus. #P < 0.05 relative to 0.02 mg/ml treatment, yP < 0.05 relative to cartilage.
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than cartilage tissue to metabolic alterations induced by these
adipokines.
Interestingly, the greater relative effects of adipokines on
meniscus are consistent with effects of interleukin-1 (IL-1) in
similar culture conditions. Meniscus sGAG release was maximal
immediately upon IL-1a treatment and steadily decreased until
sGAG depletion37 while cartilage exhibited more gradual sGAG
release that peaked at about 1 week of treatment38. Although theFig. 6. Effect of sustained adipokine exposure on explant sGAG content. sGAG content of c
difference in scaling between cartilage and meniscus. *P < 0.05 relative to controls. #P < 0patterns of catabolism induced by adipokines (primarily resistin)
and IL-1 are similar, further studies are required to determine the
extent to which common pathways are involved in the response, an
issue with implications for potential pharmacologic interventions
to address early obesity- or injury-related degeneration. It should
be noted that we used media including high glucose and insulin to
ensure high metabolic activity39 and for consistency with previous
studies examining IL-1 effects on these tissues36,38. Like cytokines
such as IL-1 and TNF-a40, some adipokines may regulate glucoseartilage (AeB) and meniscus (CeD) explants treated with adipokines for 22 h. Note the
.05 relative to 0.02 mg/ml treatment, yP < 0.05 relative to cartilage.
Fig. 7. Initial effects of adipokines on incorporation rates. Protein (3H-proline, A-D) and sGAG (35S-sulfate, E-H) incorporation rates of cartilage (A-B, E-F) and meniscus (C-D, G-
H) explants over the ﬁrst 22 h of culture with adipokines. Note the difference in scaling between cartilage and meniscus. *P < 0.05 relative to tissue-matched controls unless
otherwise indicated, #P < 0.05 relative to 0.02 mg/ml treatment, %P < 0.05 relative to 0.20 mg/ml treatment, yP < 0.05 relative to cartilage tissue.
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(both in vitro and in vivo) on adipokine-stimulated tissue catabo-
lism should be examined.
Several factors may contribute to the differential effects of adi-
pokines on cartilage and meniscus tissues. Chondrocytes and
meniscal ﬁbrochondrocytes may respond differently to the adipo-
kines, for example due to differences in receptor expression or
differences in the cellular response to a given stimulus (e.g.,
different proﬁles of secreted proteases). The extracellular matrices
(ECMs) may play a role via differential transport of adipokines into
or through the tissues, differential transport of secreted proteases,
or differential susceptibility of the ECMs to cell-mediated catabo-
lism related to differences in ECM composition and structure. These
intertwined factors could be separated to some extent by studyingthe responsiveness of isolated cells to exogenous factors, detailed
analysis of protease expression patterns, or selective use of protease
inhibitors. The microscale arrangement of the ECM and resident
cells are quite different between cartilage and meniscus, with more
mesoscale heterogeneity of meniscal matrix constituents and
localization of ﬁbrochondrocytes in the proteoglycan-enriched
matrix compartment surrounding the primary circumferential
collagen bundles41,42. This different microstructural arrangement
may play a role in the tissue-speciﬁc responsiveness to exogenous
factors, as a greater fraction of the tissue sGAG is near the cells in
meniscal tissue. Examination of the spatial distribution of protease
expression and activity through histological methods may provide
additional insights into the mechanisms behind the differential
susceptibility.
Fig. 8. Effects of sustained adipokine exposure on incorporation rates. Protein (3H-proline, AeD) and sGAG (35S-sulfate, EeH) incorporation rates of cartilage (AeB, EeF) and
meniscus (CeD, GeH) explants over the ﬁnal 22 h of 9-day cultures with adipokines. Note the difference in scaling between cartilage and meniscus. *P < 0.05 relative to tissue-
matched controls, #P < 0.05 relative to 0.02 mg/ml treatment, yP < 0.05 relative to cartilage tissue.
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release (indicative of NO production), suggesting the involvement
of active inﬂammatory pathways. Visfatin (but not leptin) was
previously reported to increase NO production in cartilage and
meniscus explants and to increase sGAG release from cartilage
explants29. Differences with our studies include culture media
(serum-supplemented vs serum-free), concentration ranges (up to
0.1 mg/ml vs 2 mg/ml) and tissue source (adult porcine vs juvenile
bovine). Immature bovine tissue has often been used to study
cartilage degradation in vitro as it provides a non-diseased blankslate to study pathological mechanisms. However, maturity can
affect cell metabolism43 and responses to catabolic stimuli44. While
effects of recombinant human adipokines have been demonstrated
on cartilaginous tissues from various species17,29,45, caution should
be exercised in directly extrapolating speciﬁc ﬁndings to human
tissue without veriﬁcation.
The dose ranges used in this study encompass pathological and
hyper-pathological concentrations. For leptin10,14,16, visfatin19,20,
and resistin12,14,17, reported concentrations in the synovial joints of
OA patients approach the lowest dose in this experiment (20 ng/
J.F. Nishimuta, M.E. Levenston / Osteoarthritis and Cartilage 23 (2015) 1551e15621560ml). It should be noted that in vivo adiponectin concentrations (up
to 2 mg/ml12,14,23) can be orders of magnitude higher than those of
the other adipokines tested, so the adiponectin doses in this study
did not reach the clearly hyper-pathological range.
In vivo animal studies with a single high dose injection of leptin
into rat knees demonstrated a catabolic response in cartilage, with
elevated MMP and aggrecanase expressions and proteoglycan
depletion46. While this response could have been mediated
through other joint tissues such as the synovium, in vitro culture
with 10 mg/ml leptin upregulated MMP activity25 and NO produc-
tion26 in human OA cartilage. In the current study, cartilage NO
release was not modulated by leptin but NO production in
meniscus was temporarily elevated, as observed previously for
cartilage26. Leptin also stimulated elevated sGAG release in
meniscus through the ﬁrst 4 days of the culture period and
inhibited sGAG incorporation in meniscus on day 1. Although leptin
decreased LDH release in both cartilage and meniscus in this study,
we found no signiﬁcant effects on LDH release in a preliminary
study. Similarly inconsistent effects of leptin on porcine myoblasts
have been reported47,48.
Visfatin increased aggrecanase (ADAMTS-4 and -5) expression
and MMP-3 and -13 synthesis by human OA chondrocytes in
monolayer11. In the current study, cartilage was minimally affected
by visfatin at the concentrations tested, which may be attributable
to differences in species and disease state but may also reﬂect
differences between monolayer and 3D tissue culture. Meniscus
sGAG release and NO production were elevated by exposure to
visfatin while initial protein and sGAG incorporations were
inhibited at the highest dose. Inhibition of meniscal sGAG incor-
poration persisted through day 9, suggesting that sustained expo-
sure to visfatin might affect tissue homeostasis.
The role in cartilage catabolism of adiponectin, which is
inversely correlated with BMI21 but associated with OA severity,
remains controversial. Adiponectin has been reported to upregu-
late TIMP-2 and downregulate interleukin-1b (IL-1b)-induced
MMP-13 production by OA human chondrocytes21, but has also
been reported to increase NO and MMP production22. We observed
no signiﬁcant effects of adiponectin on cartilage or meniscus ex-
plants, again pointing to potential differences between monolayer
and tissue culture.
Resistin downregulated collagen II and aggrecan expression and
upregulated ADAMTS-4, TNF-a, and IL-1b expression in cultured
human chondrocytes28, and induced dose-dependent depletion of
sGAG from mouse cartilage and inhibition of sGAG synthesis in
human cartilage17. In our studies, resistin was the only adipokine to
substantially stimulate cartilage sGAG release, although cartilage
sGAG content and incorporation rates were not signiﬁcantly
altered. Our results show for the ﬁrst time that resistin dramatically
increased sGAG release from meniscal tissue and substantially
reduced meniscus sGAG content, even after just 22 h of exposure,
and meniscal sGAG content was reduced to less than half that of
controls after 9-day exposure to 2 mg/ml resistin.
The strong effects of resistin are particularly interesting, as
resistin was elevated in the knee joint for several weeks following
traumatic injury17. Both meniscus and cartilage tissues undergo
immediate cell death following relatively moderate overload49,50,
despite the greater resistance of meniscus to macroscopic failure.
However, a greater susceptibility to inﬂammatory factors elevated
as part of the injury response could contribute to earlier develop-
ment of degeneration in meniscus than in articular cartilage.
Meniscus has nearly an order of magnitude less proteoglycan
content than cartilage, and small perturbations to the proteoglycan
composition can induce larger relative loss of functional mechan-
ical properties in meniscus than in cartilage37,38. Following injury,
the meniscus may be particularly susceptible to resistin-inducedsGAG depletion even in the absence of macroscopic damage
directly related to the trauma itself.
In conclusion, these studies demonstrated a greater suscepti-
bility to adipokine-induced catabolism by meniscus tissue than by
cartilage. Resistinwas the most active of the four adipokines tested,
inducing substantial sGAG depletion frommeniscal tissue explants.
This ﬁnding is particularly relevant as traumatic injury, indepen-
dent of obesity, can elevate synovial concentrations of resistin in
the knee joint. Based on these results, even a short-term exposure
to resistin can have catabolic effects in meniscal tissue. Degradation
of themeniscus thenmay stimulate cartilage degradation, either by
altering the local mechanical environment or biologically stimu-
lating catabolism. As obesity continues to be a national epidemic,
understanding the systemic consequences of increased adiposity is
important in evaluating its impact on the lifestyles of those at risk.
Investigations into the complex interactions between biologic and
mechanical factors in knee joint health are not only valuable to
understand the etiology of OA, but may also reveal novel targets for
early diagnosis or pharmaceutical intervention.
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